Tag: FWB:18H

October 29, 2019

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Medical Inc. (CSE:PREV,  OTCQB:PRVCF, FSE:18H) (the “Company” or “PreveCeutical”), is pleased to announce the successful completion of the design, synthesis and...
October 7, 2019

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund

PreveCeutical Medical Inc. is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian...
September 23, 2019

PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Medical Inc. (CSE:PREV, OTCQB: PRVCF, FSE:18H), is pleased to provide an update on its dual gene therapy program.
September 3, 2019

PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant...